AC
SGMO

Athanor Capital’s SANGAMO THERAPEUTICS INC SGMO Stock Holding History

Athanor Capital’s Portfolio SGMO Stock Details SGMO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-36,248
Closed -$454K – 723
2021
Q1 		$454K Hold
36,248
– – 0.01% 507
2020
Q4 		$566K Buy
36,248
+5,567
+18% +$65.2K 0.01% 437
2020
Q3 		$290K Buy
+30,681
New +$332K 0.01% 438

Other funds holding SGMO

WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Athanor Capital's SGMO Position: Q2 2021 in Review

Athanor Capital sold out of SANGAMO THERAPEUTICS INC (SGMO) in Q2 2021, closing a stake of 36,248 shares — an estimated $454K sold.

Athanor Capital first reported a position in SGMO in Q3 2020 and held it in 3 quarters. The position peaked at $566K in Q4 2020. 197 funds tracked by Wall St. Rank hold SGMO as of Q2 2021.

  • Athanor Capital reported no remaining SANGAMO THERAPEUTICS INC position as of Q2 2021 after selling out during the quarter.
  • Athanor Capital sold 36,248 SANGAMO THERAPEUTICS INC shares in Q2 2021, an estimated $454K.
  • Athanor Capital first reported a position in SANGAMO THERAPEUTICS INC in Q3 2020 and held it in 3 quarters.
  • Athanor Capital's SANGAMO THERAPEUTICS INC position peaked at $566K in Q4 2020.
  • 197 funds tracked by Wall St. Rank held SANGAMO THERAPEUTICS INC as of Q2 2021.

Based on Athanor Capital's 13F filing for Q2 2021, filed 16 Aug 2021.